Neuronetics (STIM): Customer relationships that drive NeuroStar revenue — what investors need to know
Neuronetics monetizes a medical-device + services model: it sells NeuroStar Advanced Therapy Systems (capital hardware), captures recurring revenue from treatment sessions and consumables, and supplements sales with service, warranties and clinic revenues through its Greenbrook treatment centers. Revenue is heavily U.S.-centric and recurring-session dependent, and recent strategic customer agreements and the Greenbrook integration materially reshape how capital sales and clinic revenue flow into the top line. For a deeper look at how those customer ties influence execution and risk, visit https://nullexposure.com/.
The short thesis: monetization and commercial posture, in plain English
Neuronetics is a commercial-stage medical device company that earns most of its revenue from recurring treatment sessions, backed by initial capital sales of NeuroStar systems and service contracts. The company sells direct in the U.S., uses distributors in select international markets, operates treatment clinics through its Greenbrook footprint, and offers longer-term customer financing options such as three- or four-year rent-to-own leases. This mix gives the company predictable recurring revenue but creates concentration and operational dependence on U.S. clinic demand and multi-year customer contracts. Learn more at https://nullexposure.com/.
Who the customers and partners are — and why each matters
Below I cover every customer relationship mentioned in the available filings and press coverage, with concise, source-linked summaries.
-
Elite DNA Behavioral Health
Elite DNA signed an exclusive three‑year agreement to make NeuroStar the sole TMS device provider across its 30+ Florida locations, giving Neuronetics a channel into a large, fast‑growing regional behavioral-health network. (See Neuronetics press release via GlobeNewswire, Oct 30, 2025: https://www.globenewswire.com/news-release/2025/10/30/3177422/0/en/Neuronetics-Announces-Three-Year-Exclusive-Partnership-with-Elite-DNA-Behavioral-Health-to-Expand-NeuroStar-Access-and-Operational-Excellence.html.) -
Transformations Care Network
Transformations Care Network continues to expand its multi‑state footprint of NeuroStar systems under an ongoing agreement, reinforcing Neuronetics’ strategy of selling capital systems into growing clinic groups that deliver recurring session revenue. (Reported in RTTNews coverage of historical guidance and customer expansion, FY2022: https://www.rttnews.com/amp/3284184/neuronetics-expects-5-to-12-revenue-growth-in-2022.aspx.) -
Greenbrook TMS / Greenbrook TMS Inc.
Greenbrook is the largest and most strategically significant commercial relationship: Neuronetics acquired Greenbrook clinics and integrated clinic revenue into its U.S. results, with the company removing non‑performing clinics post‑acquisition and adjusting historical comparatives. The Greenbrook transaction materially increased reported clinic revenue (for example, U.S. clinic revenue noted at $21.8 million in a CityBiz report tied to FY2025 results) and is referenced in Neuronetics’ preliminary FY2025/FY2026 reporting summaries. (See QuiverQuant summary of preliminary FY2025/FY2026 results and adjustments: https://www.quiverquant.com/news/Neuronetics%2C+Inc.+Reports+Strong+Preliminary+Financial+Results+for+Fourth+Quarter+and+Full+Year+2025%2C+Highlighting+Significant+Revenue+Growth; and CityBiz coverage of Q3 2025 results and CEO transition noting Greenbrook-related revenue at $21.8M: https://www.citybiz.co/article/767284/neuronetics-reports-q3-2025-results-and-announces-ceo-transition-plan/). An earlier CityBiz item notes Greenbrook as an exclusive national account in the company’s strategic partnerships (FY2023 context): https://www.citybiz.co/article/383293/neuronetics-elevates-sara-grubbs-to-svp-chief-revenue-officer/.
What the customer map implies about Neuronetics’ operating model
The relationship evidence and company disclosures produce a clear operational profile:
-
Contracting posture — longer term and capital‑intensive. Company disclosures describe rent‑to‑own lease structures with three‑ or four‑year terms for NeuroStar systems, indicating a customer base that often commits multi‑year and which smooths capital sales into predictable cash streams through lease-to-own economics. This is a company‑level signal drawn from Neuronetics’ contractual descriptions rather than any single customer excerpt.
-
Geographic concentration — overwhelmingly U.S. revenue. Neuronetics generates the vast majority of its revenue in the United States (noted at 97% for 2023–2024), sold primarily through a direct U.S. sales force. That concentration is a material commercial characteristic and increases sensitivity to U.S. reimbursement dynamics and clinic demand.
-
Revenue mix and criticality — recurring sessions drive economics. The company states that it derives the majority of NeuroStar revenue from recurring treatment sessions, with capital sales and service contracts augmenting that base. That makes clinic partners and high‑utilization networks (like Elite DNA and Greenbrook clinics) critical to both utilization and long‑term cash generation.
-
Role diversity — Neuronetics is seller, operator and partner. The company is simultaneously a hardware seller (capital systems), a services provider (treatment sessions and clinic operations via Greenbrook), and a distributor partner internationally in a limited set of markets. This blended role increases operational complexity but also creates multiple levers to convert device placements into ongoing revenue.
-
Relationship stage — active commercial rollout and integration. Customer references and recent press describe ongoing, active commercial expansions and the operational integration of Greenbrook clinics, signaling a company in consolidation and scale‑up mode rather than a nascent commercial pilot.
Investment implications: upside and risk framed by customers
The customer landscape creates a specific set of investment implications for STIM holders and analysts:
-
Upside drivers
- Network agreements (Elite DNA) and the Greenbrook integration can accelerate recurring-session revenue, improving revenue visibility and incremental margin as utilization grows.
- Rent‑to‑own terms lock in long duration value from capital placements, smoothing revenue recognition and supporting lifetime‑value economics for each system placement.
-
Key risks
- High U.S. concentration (97% of revenue) elevates policy and reimbursement risk; any adverse changes to payor behavior disproportionately affect Neuronetics.
- Execution risk on clinic performance and non‑performing locations — management already closed underperforming Greenbrook clinics post‑acquisition, demonstrating the operational work required to realize synergies.
- Dependence on a small number of large national accounts creates concentration risk if any exclusive partner relationship shifts.
For investors who want to evaluate counterparty exposure and the durability of recurring revenue, Neuronetics’ customer ties are a primary barometer. For more detailed customer‑level signal analysis and monitoring, visit https://nullexposure.com/.
Final read: what to watch next
Monitor three things to track whether customer relationships convert into durable value: (1) clinic utilization trends and treatment‑session growth, (2) lease and service contract roll‑outs with large behavioral‑health networks, and (3) U.S. reimbursement or regulatory changes that affect session economics. Together these will determine whether Neuronetics’ hardware sales translate into predictable, high‑margin recurring revenue.
If you want structured monitoring of these customer relationships and how they influence STIM’s revenue run‑rate, explore the research tools at https://nullexposure.com/ for ongoing coverage and alerts.